U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep.

Cover of Clinical Review Report: Levodopa/Carbidopa (Duodopa)

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

Show details

References

1.
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003 Apr 3;348(14):1356–64. [PubMed: 12672864]
2.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001 May;16(3):448–58. [PubMed: 11391738]
3.
Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009 Jun 13;373(9680):2055–66. [PubMed: 19524782]
4.
Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007 Sep;13 Suppl:S13–S17. [PubMed: 17707679]
5.
Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, et al. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol. 2013 May;12(5):514–24. [PubMed: 23582175]
6.
Jankovic J. Etiology and pathogenesis of Parkinson disease. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2017 [cited 2018 Apr 19]. Available from: www​.uptodate.com Subscription required.
7.
Canadian guidelines on Parkinson’s disease. Can J Neurol Sci [Internet]. 2012 [cited 2018 Apr 19];39(4 Suppl 4). Available from: http://www​.parkinsonclinicalguidelines​.ca​/sites/default/files​/PD_Guidelines_2012.pdf
8.
Tarsy D. Pharmacologic treatment of Parkinson disease. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2017 [cited 2018 Apr 19]. Available from: www​.uptodate.com Subscription required.
9.
PrDuodopa® (levodopa/carbidopa intestinal gel): intestinal gel (1 mL contains 20 mg levodopa and 5 mg carbidopa monohydrate) [product monograph]. St. Laurent (QC): AbbVie Corporation; 2017 Apr 27.
10.
Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, et al. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson’s Disease. Mov Disord Clin Pract. 2017 Nov;4(6):829–37. [PMC free article: PMC5724683] [PubMed: 29242809]
11.
Pickut BA, van der Linden C, Dethy S, Van De Maele H, de Beyl DZ. Intestinal levodopa infusion: the Belgian experience. Neurol Sci. 2014 Jun;35(6):861–6. [PubMed: 24379105]
12.
Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat Disord. 2017 Dec;45:13–20. [PubMed: 29037498]
13.
Annic A, Devos D, Seguy D, Dujardin K, Destee A, Defebvre L. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: Efficacy and safety]. Rev Neurol (Paris). 2009 Aug;165(8-9):718–27. [PubMed: 19150100]
14.
Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. J Clin Neurosci. 2016 Mar;25:41–5. [PubMed: 26777085]
15.
De Fabregues O, Dot J, bu-Suboh M, Hernandez-Vara J, Ferre A, Romero O, et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav [Internet]. 2017 Aug [cited 2018 Jun 1];7(8):e00758. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC5561319 [PMC free article: PMC5561319] [PubMed: 28828219]
16.
Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009 Jul 30;24(10):1468–74. [PubMed: 19425079]
17.
Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A, et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open-label study. Parkinsonism Relat Disord. 2017 Apr;37:79–86. [PubMed: 28185758]
18.
Kruger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, De FO, et al. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients. Adv Ther [Internet]. 2017 Jul [cited 2018 Jun 1];34(7):1741–52. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC5504221 [PMC free article: PMC5504221] [PubMed: 28631218]
19.
Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016 Mar;23(3):501–9. [PubMed: 26498913]
20.
Merola A, Zibetti M, Rizzone MG, Troiano M, Artusi CA, Angrisano S, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand. 2014 Jan;129(1):e1–e5. [PubMed: 23834498]
21.
Murata M, Mihara M, Hasegawa K, Jeon B, Tsai CH, Nishikawa N, et al. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. NPJ Parkinsons Dis [Internet]. 2016 [cited 2018 Jun 1];2:16020. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC5516619 [PMC free article: PMC5516619] [PubMed: 28725701]
22.
Skoromets AA, Odinak MM, Yakupov EZ, Litvinenko IV, Zalyalova ZA, Timofeeva AA, et al. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2):22–31. [PubMed: 28374689]
23.
Timpka J, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, et al. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson’s disease. Acta Neurol Scand. 2016 Jun;133(6):451–8. [PubMed: 26358227]
24.
Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol. 2014 Feb;21(2):312–8. [PubMed: 24313838]
25.
Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013 Jan;260(1):105–14. [PubMed: 22772358]
26.
Clinical Study Report: R&D/11/995. A randomized, double-blind, double-dummy, efficacy, safety, and tolerability study of levodopa-carbidopa intestinal gel in levodopa-responsive Parkinson’s subjects receiving optimized treatments with Parkinson medicinal products who continue to experience persistent motor fluctuations [CONFIDENTIAL internal manufacturer’s report]. Abbott Park (IL): Abbott Laboratories; 2012 Oct 31.
27.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141–9. [PMC free article: PMC4643396] [PubMed: 24361112]
28.
Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord [Internet]. 2015 Apr [cited 2018 Mar 23];30(4):500–9. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC4674978/pdf/mds0030-0500.pdf [PMC free article: PMC4674978] [PubMed: 25545465]
29.
Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896–912. [PubMed: 25904081]
30.
Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B. Levodopa-induced plasticity: a double-edged sword in Parkinson’s disease? Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672). [PMC free article: PMC4455753] [PubMed: 26009763]
31.
Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ. 2011;14(5):584–93. [PubMed: 21728911]
32.
Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat Disord [Internet]. 2013 Mar [cited 2018 Mar 23];19(3):339–45. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC3661282/pdf/nihms460729.pdf [PMC free article: PMC3661282] [PubMed: 23287001]
33.
Dewey RB, Jr. Management of motor complications in Parkinson’s disease. Neurology. 2004 Mar 23;62(6 Suppl 4):S3–S7. [PubMed: 15037664]
34.
Konitsiotis S. Novel pharmacological strategies for motor complications in Parkinson’s disease. Expert Opin Invest Drugs. 2005 Apr;14(4):377–92. [PubMed: 15882115]
35.
Martinez-Martin P, Forjaz MJ, Frades-Payo B, Rusinol AB, Fernandez-Garcia JM, Benito-Leon J, et al. Caregiver burden in Parkinson’s disease. Mov Disord. 2007 May 15;22(7):924–31. [PubMed: 17238193]
36.
Global Parkinson’s Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002 Jan;17(1):60–7. [PubMed: 11835440]
37.
Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson’s disease. Mov Disord. 1998 May;13(3):406–13. [PubMed: 9613729]
38.
Keranen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003 Jan;9(3):163–8. [PubMed: 12573872]
39.
Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000 Nov;15(6):1112–8. [PubMed: 11104193]
40.
Carter JH, Stewart BJ, Archbold PG, Inoue I, Jaglin J, Lannon M, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Mov Disord. 1998 Jan;13(1):20–8. [PubMed: 9452321]
41.
Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro CJ, et al. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord. 2008 Sep 15;23(12):1673–80. [PubMed: 18709684]
42.
Martinez-Martin P, ito-Leon J, Alonso F, Catalan MJ, Pondal M, Zamarbide I, et al. Quality of life of caregivers in Parkinson’s disease. Qual Life Res. 2005 Mar;14(2):463–72. [PubMed: 15892435]
43.
Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235–45. [PubMed: 16488379]
44.
Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010 Apr 30;25(6):704–9. [PubMed: 20437539]
45.
Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996 May;14(2):317–35. [PMC free article: PMC7173037] [PubMed: 8827174]
46.
Wong SL, Gilmour H, Ramage-Morin PL. Parkinson’s disease: Prevalence, diagnosis and impact. Health Rep. 2014 Nov;25(11):10–4. [PubMed: 25408491]
47.
Canadian Community Health Survey (CCHS), custom tabulation. 2000-2001 [Internet]. Ottawa: Statistics Canada; 2002. [cited 2018 Apr 19]. Available from: http://www23​.statcan​.gc.ca/imdb/p2SV.pl?Function​=getSurvey&SurvId​=1630&InstaId=3359
48.
Mapping connections: an understanding of neurological conditions in Canada [Internet]. Ottawa: Government of Canada; 2014. [cited 2018 Apr 19]. Available from: https://www​.canada.ca​/en/public-health/services​/reports-publications​/mapping-connections-understanding-neurological-conditions.html
49.
Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–9. [PubMed: 8190296]
50.
Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, et al. Gastric emptying time and gastric motility in patients with Parkinson’s disease. Mov Disord. 2001 Nov;16(6):1041–7. [PubMed: 11748735]
51.
Deep-Brain Stimulation for Parkinson’s Disease Study Group, Obeso JA, Olanow CW, Rodriguez-Oroz MC, Krack P, Kumar R, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001 Sep 27;345(13):956–63. [PubMed: 11575287]
52.
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26: Suppl 3:S2–41. [PubMed: 22021173]
53.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Summary review. In: Levodopa-Carbidopa Intestinal Gel (LCIG). Company: AbbVie Inc. Application no.: 203952. Approval date: 01/09/2015 [Internet]. Rockville (MD): FDA; 2015 Jan 9 [cited 2018 Apr 19]. (FDA drug approval package). Available from: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2015/203952Orig1s000SumR.pdf
54.
PrMirapex® (pramipexole dihydrochloride tabltes): tablets 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, 1.5 mg pramipexole dihydrochloride monohydrate [product monograph] [Internet]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2018. [cited 2018 Apr 19]. Available from: https://pdf​.hres.ca/dpd_pm/00043483.PDF
55.
PrSinemet® CR (levodopa and carbidopa controlled release tablets): 100 mg/25 mg, 100 mg levodopa and 25 mg carbidopa, 200 mg/50 mg, 200 mg levodopa and 50 mg carbidopa [product monograph] [Internet]. Kirkland (QC): Merck Canada Inc. 2014. [cited 2018 Apr 19]. Available from: https://pdf​.hres.ca/dpd_pm/00023855.PDF
56.
PrProlopa® (levodopa and bensarazide capsules): 50 mg - 12.5 mg, 100 mg - 25 mg, 200 mg - 50 mg [product monograph] [Internet]. Mississauga (ON): Hoffmann-La Roche Limited; 2018. [cited 2018 Apr 19]. Available from: https://pdf​.hres.ca/dpd_pm/00043528.PDF
57.
PrAPO-Ropinirole (Ropinirole hydrochloride tablets USP): 0.25 mg, 0.5 mg, 1mg, 2 mg, 3 mg, 4 mg and 5 mg ropinirole (as ropinirole hydrochloride) [product monograph] [Internet]. Toronto (ON): Apotex Inc.; 2017. [cited 2018 Apr 19]. Available from: https://pdf​.hres.ca/dpd_pm/00041774.PDF
58.
PrNeupro® (rotigotine): 1 mg/24 h, 2 mg/24h, 3 mg/24h, 4 mg/24h, 6 mg/24h, 8 mg/24h rotigine [product monograph] [Internet]. Oakville (ON): UCB Canada; 2017. [cited 2018 Apr 19]. Available from: https://pdf​.hres.ca/dpd_pm/00044632.PDF
59.
Common Drug Review. CEDAC final recommendation or reconsideration and reasons for recommendation: Levodopa/Carbidopa (Duodopa™ Solvay Pharma Inc.). Indicaton: Parkinson’s disease [Internet]. Ottawa: CADTH; 2009. [cited 2018 Apr 20]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/cdr_complete​_Duodopa_July_24_2009.pdf
60.
Hirsch LJ. Corrections to Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel or patients with advanced Parkinson’s disease: A randomised, controlled, double-blind, double-dummy study. The Lancet Neurology. 2014;13(3):240. [PMC free article: PMC4643396] [PubMed: 24361112]
61.
Hauser RA, Auinger P, Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord. 2011 Apr;26(5):813–8. [PubMed: 21437987]
62.
Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing. 2001 Jul;30(4):299–302. [PubMed: 11509307]
63.
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014;2014:467131. [PMC free article: PMC3995302] [PubMed: 24800101]
64.
Xin Y, McIntosh E. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review. Qual Life Res. 2017 Jan;26(1):1–23. [PubMed: 27778141]
65.
Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000 Mar;23(2):75–81. [PubMed: 10803796]
66.
Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071–9. [PMC free article: PMC1738605] [PubMed: 12876237]
67.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Duopa (carbidopa and levodopa enteral suspension = CLES). Abbvie Pharmaceuticals. Application no.: 2039520. Approval date: 01/09/2015 [Internet]. Rockville (MD): FDA; 2015 Jan 9 [cited 2018 Feb 22]. (FDA drug approval package). Available from: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2015/203952Orig1s000MedR.pdf
68.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Levodopa-Carbidopa Intestinal Gel (LCIG). Company: AbbVie Inc. Application no.: 203952. Approval date: 01/09/2015 [Internet]. Rockville (MD): FDA; 2015 Jan 9 [cited 2018 Feb 22]. (FDA drug approval package). Available from: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2015/203952Orig1s000StatR.pdf
69.
Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003 May;26(3):156–63. [PubMed: 12782919]
70.
Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005 Jan 25;64(2):216–23. [PubMed: 15668416]
71.
Caceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fernandez I, Vargas-Gonzalez L, Carballo M, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease. J Neurol. 2014 Mar;261(3):561–9. [PubMed: 24477490]
72.
Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord [Internet]. 2016 Apr [cited 2018 Mar 20];31(4):530–7. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC5066747/pdf/MDS-31-530.pdf [PMC free article: PMC5066747] [PubMed: 26817533]
73.
Guthikonda LN, Lyons KE, Pahwa R. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson’s disease. J Comp Eff Res. 2014 Jul;3(4):331–3. [PubMed: 25275230]
74.
Jugel C, Ehlen F, Taskin B, Marzinzik F, Muller T, Klostermann F. Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE [Internet]. 2013 [cited 2018 Mar 20];8(6):e66639. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC3688609/pdf/pone.0066639.pdf [PMC free article: PMC3688609] [PubMed: 23818953]
75.
Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology. 1993 Sep;43(9):1698–703. [PubMed: 8414015]
76.
Karlsborg M, Korbo L, Regeur L, Glad A. Duodopa pump treatment in patients with advanced Parkinson’s disease. Ugeskr Laeger. 2010 Jun 7;172(23):1745. In Danish. [PubMed: 20552745]
77.
Hauser RA, Deckers F, Lehert P. Parkinson’s disease home diary: further validation and implications for clinical trials. Mov Disord. 2004 Dec;19(12):1409–13. [PubMed: 15390057]
78.
Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995 Jun;4(3):241–8. [PubMed: 7613534]
79.
Bushnell DM, Martin ML. Quality of life and Parkinson’s disease: translation and validation of the US Parkinson’s Disease Questionnaire (PDQ-39). Qual Life Res. 1999 Jun;8(4):345–50. [PubMed: 10472167]
80.
Damiano AM, Snyder C, Strausser B, Willian MK. A review of health-related quality-of-life concepts and measures for Parkinson’s disease. Qual Life Res. 1999 May;8(3):235–43. [PubMed: 10472154]
81.
Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol. 1998 May;245: Suppl 1:S10–S14. [PubMed: 9617716]
82.
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997 Sep;26(5):353–7. [PubMed: 9351479]
83.
Jenkinson C, Fitzpatrick R, Norquist J, Findley L, Hughes K. Cross-cultural evaluation of the Parkinson’s Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol. 2003 Sep;56(9):843–7. [PubMed: 14505768]
84.
Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, et al. Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of life. Qual Life Res. 2000 Feb;9(1):87–100. [PubMed: 10981209]
85.
Harrison JE, Preston S, Blunt SB. Measuring symptom change in patients with Parkinson’s disease. Age Ageing. 2000 Jan;29(1):41–5. [PubMed: 10690694]
86.
Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011 Nov;26(13):2371–80. [PubMed: 21735480]
87.
Jesus-Ribeiro J, Vieira E, Ferreira P, Januario C, Freire A. Reliability and Validity of 39-Item Parkinson’s Disease Questionnaire and Parkinson’s Disease Quality of Life Questionnaire. Acta Med Port. 2017 May 31;30(5):395–401. [PubMed: 28865504]
88.
Kwon DY, Kim JW, Ma HI, Ahn TB, Cho J, Lee PH, et al. Translation and validation of the korean version of the 39-item Parkinson’s disease questionnaire. J Clin Neurol. 2013 Jan;9(1):26–31. [PMC free article: PMC3543906] [PubMed: 23346157]
89.
Morley D, Dummett S, Kelly L, Dawson J, Jenkinson C. Evaluating the psychometric properties of an e-based version of the 39-item Parkinson’s Disease Questionnaire. Health Qual Life Outcomes. 2015 Jan 23;13:5. [PMC free article: PMC4311489] [PubMed: 25613007]
90.
Park HJ, Sohng KY, Kim S. Validation of the Korean version of the 39-Item Parkinson’s Disease Questionnaire (PDQ-39). Asian Nurs Res (Korean Soc Nurs Sci). 2014 Mar;8(1):67–74. [PubMed: 25030495]
91.
Nojomi M, Mostafavian Z, Shahidi GA, Jenkinson C. Quality of life in patients with Parkinson’s disease: translation and psychometric evaluation of the Iranian version of PDQ-39. J Res Med Sci. 2010 Mar;15(2):63–9. [PMC free article: PMC3082793] [PubMed: 21526061]
92.
Hagell P. Feasibility and linguistic validity of the Swedish version of the PDQ-39. Expert Rev Pharmacoecon Outcomes Res. 2005 Apr;5(2):131–6. [PubMed: 19807568]
93.
Morley D, Dummett S, Kelly L, Dawson J, Jenkinson C. An electronic version of the PDQ-39: acceptability to respondents and assessment of alternative response formats. J Parkinsons Dis. 2014;4(3):467–72. [PubMed: 24670486]
94.
Zhang JL, Chan P. Reliability and validity of PDQ-39: a quality-of-life measure for patients with PD in China. Qual Life Res. 2012 Sep;21(7):1217–21 [PubMed: 21983714]
95.
Luo W, Gui XH, Wang B, Zhang WY, Ouyang ZY, Guo Y, et al. Validity and reliability testing of the Chinese (mainland) version of the 39-item Parkinson’s Disease Questionnaire (PDQ-39). J Zhejiang Univ Sci B. 2010 Jul;11(7):531–8. [PMC free article: PMC2897024] [PubMed: 20593519]
96.
Krikmann U, Taba P, Lai T, Asser T. Validation of an Estonian version of the Parkinson’s Disease Questionnaire (PDQ-39). Health Qual Life Outcomes. 2008 Mar 25;6:23. [PMC free article: PMC2335093] [PubMed: 18364047]
97.
Carod-Artal FJ, Martinez-Martin P, Vargas AP. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord. 2007 Jan;22(1):91–8. [PubMed: 17094102]
98.
Kim MY, Dahlberg A, Hagell P. Respondent burden and patient-perceived validity of the PDQ-39. Acta Neurol Scand. 2006 Feb;113(2):132–7. [PubMed: 16411975]
99.
Ma HI, Hwang WJ, Chen-Sea MJ. Reliability and validity testing of a Chinese-translated version of the 39-item Parkinson’s Disease Questionnaire (PDQ-39). Qual Life Res. 2005 Mar;14(2):565–9. [PubMed: 15892447]
100.
Luo N, Tan LC, Li SC, Soh LK, Thumboo J. Validity and reliability of the Chinese (Singapore) version of the Parkinson’s Disease Questionnaire (PDQ-39). Qual Life Res. 2005 Feb;14(1):273–9. [PubMed: 15789961]
101.
Tan LC, Luo N, Nazri M, Li SC, Thumboo J. Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson’s disease patients in Singapore. Parkinsonism Relat Disord. 2004 Dec;10(8):493–9. [PubMed: 15542010]
102.
Serrano-Duenas M, Martinez-Martin P, Vaca-Baquero V. Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) (PDQL-EV). Parkinsonism Relat Disord. 2004 Oct;10(7):433–7. [PubMed: 15465402]
103.
Hagell P, McKenna SP. International use of health status questionnaires in Parkinson’s disease: translation is not enough. Parkinsonism Relat Disord. 2003 Dec;10(2):89–92. [PubMed: 14643998]
104.
Kohmoto J, Ohbu S, Nagaoka M, Suzukamo Y, Kihira T, Mizuno Y, et al. [Validation of the Japanese version of the Parkinson’s Disease Questionnaire]. Rinsho Shinkeigaku. 2003 Mar;43(3):71–6. [PubMed: 12820553]
105.
Tsang KL, Chi I, Ho SL, Lou VW, Lee TM, Chu LW. Translation and validation of the standard Chinese version of PDQ-39: a quality-of-life measure for patients with Parkinson’s disease. Mov Disord. 2002 Sep;17(5):1036–40. [PubMed: 12360555]
106.
Auquier P, Sapin C, Ziegler M, Tison F, Destee A, Dubois B, et al. [Validation of the French language version of the Parkinson’s Disease Questionnaire - PDQ-39]. Rev Neurol (Paris). 2002 Jan;158(1):41–50. [PubMed: 11938321]
107.
Martinez-Martin P, Rojo-Abuin JM, Rodriguez-Violante M, Serrano-Duenas M, Garretto N, Martinez-Castrillo JC, et al. Analysis of four scales for global severity evaluation in Parkinson’s disease. NPJ Parkinsons Dis [Internet]. 2016;2:16007. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC5516587/pdf/npjparkd20167.pdf [PMC free article: PMC5516587] [PubMed: 28725695]
108.
Clinical impression (CGI) scale. In: Handbook of psychiatric measures. 1st. Washington (DC): American Psychiatric Association; 2000 [cited 2018 Apr 24]. p. 100–2.
109.
Seidel SE, Tilley BC, Huang P, Palesch YY, Bergmann KJ, Goetz CG, et al. Subject-investigator reproducibility of the Unified Parkinson’s Disease Rating Scale. Parkinsonism Relat Disord [Internet]. 2012 Mar [cited 2018 Apr 18];18(3):230–3. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC3288816/pdf/nihms331320.pdf [PMC free article: PMC3288816] [PubMed: 22018910]
110.
Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol. 2010 Jan;67(1):64–70. [PubMed: 20065131]
111.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129–70. [PubMed: 19025984]
112.
Holroyd S, Currie LJ, Wooten GF. Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS. Neurol Res. 2008 Jun;30(5):493–6. [PubMed: 18241530]
113.
Forjaz MJ, Martinez-Martin P. Metric attributes of the unified Parkinson’s disease rating scale 3.0 battery: part II, construct and content validity. Mov Disord. 2006 Nov;21(11):1892–8. [PubMed: 16958134]
114.
Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord. 2006 Aug;21(8):1200–7. [PubMed: 16673410]
115.
Martinez-Martin P, Forjaz MJ. Metric attributes of the unified Parkinson’s disease rating scale 3.0 battery: Part I, feasibility, scaling assumptions, reliability, and precision. Mov Disord. 2006 Aug;21(8):1182–8. [PubMed: 16673397]
116.
Metman LV, Myre B, Verwey N, Hassin-Baer S, Arzbaecher J, Sierens D, et al. Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson’s disease: an argument against multiple baseline assessments. Mov Disord. 2004 Sep;19(9):1079–84 [PubMed: 15372601]
117.
Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003 Jul;18(7):738–50. [PubMed: 12815652]
118.
Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I, et al. Test-retest reliability of the unified Parkinson’s disease rating scale in patients with early Parkinson’s disease: results from a multicenter clinical trial. Mov Disord. 2002 Jul;17(4):758–63. [PubMed: 12210871]
119.
Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994 Jan;9(1):76–83. [PubMed: 8139608]
120.
Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002 Sep;17(5):867–76. [PubMed: 12360535]
121.
Zitser J, Peretz C, Ber DA, Shabtai H, Ezra A, Kestenbaum M, et al. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec;45:7–12. [PMC free article: PMC5972376] [PubMed: 28965872]
122.
Kashihara K, Kondo T, Mizuno Y, Kikuchi S, Kuno S, Hasegawa K, et al. Official Japanese Version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale: validation against the original English version. Mov Disord Clin Pract. 2014 Sep 1;1(3):200–12. [PMC free article: PMC4199098] [PubMed: 25328906]
123.
Martinez-Martin P, Frades PB. Quality of life in Parkinson’s disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol. 1998 May;245: Suppl 1:S34–S38. [PubMed: 9617722]
124.
Horvath K, Aschermann Z, Acs P, Bosnyak E, Deli G, Pal E, et al. [Validation of the hungarian mds-updrs: Why do we need a new parkinson scale?]. Ideggyogy Sz. 2014 Mar 30;67(3-4):129–34. [PubMed: 26118257]
125.
Martinez-Martin P, Rodriguez-Blazquez C, varez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan;260(1):228–36. [PubMed: 22865238]
126.
Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, et al. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson’s Disease Rating Scale. Neurol Sci. 2013 May;34(5):683–7. [PubMed: 22678179]
127.
Brooks R. EuroQol: the current state of play. Health Policy. 1996 Jul;37(1):53–72. [PubMed: 10158943]
128.
EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208. [PubMed: 10109801]
129.
AbbVie. Levodopa-Carbidopa intestinal Ggel open-label study in advanced Parkinson’s disease. 2006 Jun 9 [cited 2018 Apr 24]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2000 -. Available from: https:​//clinicaltrials​.gov/ct2/show/study/NCT00335153 NLM Identifier: NCT00335153.
130.
CADTH Common Drug Review pharmacoeconomic review report: apomorphine (Movapo) [Internet]. Ottawa: CADTH; 2018 Feb. [cited 2018 Apr 26]. Available from: https://cadth​.ca/sites​/default/files/cdr​/pharmacoeconomic/SR0527​_Movapo_PE_Report.pdf
131.
Hagell P, Alvariza A, Westergren A, Arestedt K. Assessment of Burden Among Family Caregivers of People With Parkinson’s Disease Using the Zarit Burden Interview. J Pain Symptom Manage. 2017 Feb;53(2):272–8. [PubMed: 27810571]
132.
Smith KJ, George C, Ferriera N. Factors emerging from the “Zarit Burden Interview” and predictive variables in a UK sample of caregivers for people with dementia. Int Psychogeriatr. 2018 Mar 22;1–8. [PubMed: 29562953]
133.
Yu J, Yap P, Liew TM. The optimal short version of the Zarit Burden Interview for dementia caregivers: diagnostic utility and externally validated cutoffs. Aging Ment Health. 2018 Mar 19;1–5. [PubMed: 29553806]
134.
Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980 Dec;20(6):649–55. [PubMed: 7203086]
135.
Zarit Burden Interview (ZBI). Lyon (FR): Mapi Research Trust; 2018.
136.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159–74. [PubMed: 843571]
137.
Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013 Oct;22(8):1889–905. [PubMed: 23288613]
138.
Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9. [PubMed: 19565683]
139.
Joan Busner PaSDTM. The Clinical Global Impressions Scale Applying a Research Tool in Clinical Practice. Psychiatry (Edgmont). 2007 Jul; 4(7): 28–37. 2018. [PMC free article: PMC2880930] [PubMed: 20526405]
140.
Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson’s Rating Scale. In: Recent developments in Parkinson’s disease. Florham Park (NJ): MacMillan Health Care Information; 1987. p. 153–63, 292–304.
141.
Sinnott PL JVBPG. Preference measurement in economic analysis. Guidebook [Internet]. Menlo Park (CA): Health Economics Resource Center (HERC); 2007 Mar. 2018.
142.
Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis [Internet]. 2015 [cited 2018 Mar 20];5(1):165–74. Available from: https://content.iospress.com/download/journal-of-parkinsons-disease/jpd140456?id=journal-of parkinsons-disease%2Fjpd140456 [PubMed: 25588353]
143.
Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Mov Disord. 2018 Mar 23. [PubMed: 29570853]
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK539557
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (998K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...